29. Mär 2018
Tokyo, Japan – March 29th, 2018 - JRS PHARMA is pleased to announce that PROSOLV® SMCC (Silicified Microcrystalline Cellulose) is now monographed with the Japanese Pharmaceutical Excipients (JPE), joining the rest of JRS PHARMA’s complete portfolio of excipients solutions available in Japan.
This JPE monograph comprises all PROSOLV® SMCC grades manufactured by JRS PHARMA in the US, Finland, and Germany. Benefiting customers that both produce within, and export to, Japan, the JPE registration of PROSOLV® SMCC enables pharmaceutical manufacturers to use this high functionality excipient with fewer regulatory hurdles.
PROSOLV® SMCC, silicified microcrystalline cellulose, is a unique combination of microcrystalline cellulose (MCC) and colloidal silicon dioxide (CSD). This high functionality excipient requires less complex processing and has high inherent functionality, which it passes on to the drug formulation. Additionally, PROSOLV® SMCC offers excellent compactibility, high intrinsic flow, enhanced lubrication efficiency, improved blending properties, superior binding properties, and increased production capacity.
For more information on PROSOLV® SMCC or any of JRS PHARMA’s innovative excipient portfolio, please visit jrspharma.com or reach out to your local JRS PHARMA sales representative.
JRS PHARMA is a leading manufacturer of excipients, offering a complete portfolio of excipient solutions for the pharmaceutical and nutraceutical industries. Our excipients portfolio includes: high functionality excipients, binders, disintegrants, lubricants, functional fillers, thickeners, stabilizers, carriers, and coatings. In addition to our wide range of excipients, we offer excellent technical and formulation support to address the needs of our customers.